Multiomic Health
  • home.
  • about.
  • focus.
  • approach.
  • news.
  • team.
  • investors.
  • contact.
  • careers.
6 December 2022 by Multiomic

MultiOmic Health forges research collaboration with Northern Care Alliance NHS Foundation Trust in diabetic kidney disease

MultiOmic Health forges research collaboration with Northern Care Alliance NHS Foundation Trust in diabetic kidney disease
6 December 2022 by Multiomic

TUE, 06/12/2022 – 07:30

London, United Kingdom, 6th December 2022 / Sciad Newswire / MultiOmic Health, an artificial intelligence-enabled precision medicine discovery company, today announces the signing of a research collaboration agreement with Northern Care Alliance (NCA) NHS Foundation Trust in Manchester, England. MultiOmic will deploy its MOHSAIC® platform on de-identified bio-samples and clinical histories previously collected by NCA to investigate patient stratifying biomarkers in diabetic nephropathy using integrative multi-omics analyses.

“This collaboration involves our Salford Kidney Study (one of the largest chronic kidney disease cohorts in the world) with a specific focus on a diabetic sub-cohort,” said Professor Philip Kalra, Director of Research & Innovation at NCA and a leading kidney specialist in UK clinical research and nephrologist education. “I am particularly excited by the use of multiple omics modalities in the analysis which could lead to new insights that greatly improve patient prognosis. This is a major step on the way towards personalised medicine in a very common but serious condition.”

“Diabetic nephropathy is a chronic multi-factorial disease driven by a complex interplay between inherited factors and the cumulative effect of diet, lifestyle and environmental exposures,” said Slaven Stekovic, Chief Scientific Officer at MultiOmic.

“Traditional genome-wide association studies (GWAS) looking only at the genome have been unable to explain the disease progression of the vast majority of chronic kidney disease patients,” said Ariella Cohain, Chief Technology Officer at MultiOmic. “By integrating the genome, epigenome, proteome and metabolome, we aim to gain a deeper understanding of all the factors which drive this debilitating disease.”

An estimated 30% to 40% of diabetics eventually develop chronic kidney disease1. Diabetic kidney disease patients now account for an estimated $300 billion per year2 in global healthcare costs. Recently published research indicates that the risk of developing type 2 diabetes3 or incurring kidney damage4 in later life is increased in COVID-19 survivors, leading to an expected acceleration in disease prevalence over the next two decades.

For avoidance of doubt, all patient information provided to MultiOmic by its research collaborators is de-identified, fully consented and in compliance with relevant privacy and data protection legislation, regulations and guidance, including but not limited to the General Data Protection Regulation (GDPR) in both the European Union and the United Kingdom.

ENDS

For further information, please contact:

MultiOmic Health
Esra Berkol
E: esra@multiomic.health

NCA
Claire Mooney
E: Claire.Mooney@nca.nhs.uk

Sciad Communications, Media Relations
Richard Anderson / Sophie Protheroe
E: multiomic@sciad.com

Notes to Editors

About MultiOmic Health

MultiOmic Health is an AI-enabled drug discovery (AIDD) company dedicated to chronic multi-factorial diseases, with an initial focus on the metabolic syndrome-related conditions. It partners with research institutions, healthcare providers and healthtech companies to source de-identified patient data and bio-samples. Drawing upon these carefully selected data sources, MultiOmic’s MOHSAIC® platform combines integrated multi-omics analysis and computational systems biology modeling with targeted wet laboratory experiments to originate novel precision therapeutic concepts. MultiOmic subsequently partners with established biopharma companies to take its therapeutic concepts into global clinical trial programs and market the ensuing medicines. Its experienced leadership team blends commercial, technical and operational expertise from across the pharma, systems biology and AI/big data arenas.

About Northern Care Alliance

Northern Care Alliance NHS Foundation Trust was established on 1 October 2021 bringing together Salford Royal NHS Foundation Trust and The Pennine Acute Hospitals NHS Trust. NCA provides hospital and community healthcare services in Salford, Oldham, Bury and Rochdale. Its dedicated team of around 20,000 staff delivers high standards of care and experience excellence to over one million people across Greater Manchester and beyond.

References

1. ‘Shared professional practice on kidney care and diabetes’, Diabetes UK.
Webpage: https://www.diabetes.org.uk/professionals/resources/shared-practice/kidney-care
2. MultiOmic Health estimates based on global forecasts of spending on T2D and CKD for patients with both conditions using data from the WHO, CMS, IDF and CDC.
3. ‘Diabetes risk rises after COVID’, Nature (2022). Article: https://www.nature.com/articles/d41586-022-00912-y
4. ‘Covid-19: Infection increases the risk of kidney disease even in mild cases’, British Medical Journal (2021). Article: https://www.bmj.com/content/374/bmj.n2189

Previous articleHonoured to be selected as winners of BIA's Innovation Showcase in the first ever TechBioUK conference

About Multiomic

Multiomic is a next-generation precision medicine business, applying computational systems biology to develop and commercialize data assets for metabolic syndrome — the world’s largest healthcare burden.

With our unique combination of data science and biology expertise, we are enabling data-driven development of therapeutics and are bringing understanding into complex biological systems.

Recent Posts

MultiOmic Health forges research collaboration with Northern Care Alliance NHS Foundation Trust in diabetic kidney disease6 December 2022
Honoured to be selected as winners of BIA’s Innovation Showcase in the first ever TechBioUK conference17 October 2022
Leveraging AI to Tackle the Looming Metabolic Syndrome Crisis4 October 2022

Categories

  • Articles
  • Blog Post
  • Interview
  • News
  • Podcast
  • Press Release

Tags

AI BIA Conference Drug Discovery Feature Mesh Bio Metabolic Syndrome MOHSAIC Multiomic Health Nature NCA Omics Partnership Podcast Precision Medicine Press Release Robert Thong TechBio UK The Pharma Letter

About

Multiomic Health Limited is a next-generation precision medicine business, applying computational systems biology to develop  and commercialize data assets for metabolic syndrome

Contact

info@multiomic.healthhttps://multiomic.health/
Multiomic Health Limited. All Rights Reserved.

© Multiomic Health Limited 2021. All Rights Reserved.

Multiomic Health Limited is a Registered UK Company

Company Number: 13246608

Company Address: Epworth House, 25 City Road, Shoreditch, London, EC1Y 1AA

CONTACT

info@multiomic.health

COPYRIGHT notice

All the content on multiomic.health is either self-generated by Multiomic Health Limited, or readily available in various places on the Internet and therefore believed to be in the public domain. Transparent PNG images uploaded are believed to be posted within our rights according to the U.S. Copyright Fair Use Act (Title 17, U.S. Code.) and comparable regulations in other countries.

multiomic.health complies with 17 U.S.C. 512 and the Digital Millennium Copyright Act (“DMCA”). It is our policy to respond to any infringement notices and take appropriate actions under the DMCA and other applicable intellectual property laws.

If by any chance your copyrighted material has been posted on multiomic.health or if links to your copyrighted material are returned through a search engine and you wish this material removed, please provide a written statement identifying in sufficient detail the copyrighted work claimed to have been infringed. You may use the contact form at the end of the landing page for the purposes of such written communication.

 

DATA SOURCES

https://ourworldindata.org/causes-of-death

https://ourworldindata.org/obesity

https://bmjopen.bmj.com/content/10/8/e036663

How Prevalent is NASH?

https://www.heart.org/-/media/phd-files-2/science-news/2/2021-heart-and-stroke-stat-update/2021_heart_disease_and_stroke_statistics_update_fact_sheet_at_a_glance.pdf?la=en

https://www.ahajournals.org/doi/10.1161/CIR.0000000000000757

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278808/

https://www.cdc.gov/obesity/data/adult.html

https://stop.publichealth.gwu.edu/sites/stop.publichealth.gwu.edu/files/documents/Fast%20Facts%20Cost%20of%20Obesity.pdf

https://www.sciencedirect.com/science/article/abs/pii/S2211883717300187

https://journals.lww.com/jcge/Abstract/2015/09000/The_Epidemiology_of_Cirrhosis_in_the_United.12.aspx#:~:text=The%20prevalence%20of%20cirrhosis%20in%20the%20United%20States%20was%20approximately,unaware%20of%20having%20liver%20disease

How Prevalent is NASH?

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743497/#:~:text=In%20the%20United%20States%2C%20NAFLD,nearly%2025%25%20progress%20to%20NASH

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767767/

https://www.nature.com/articles/nrgastro.2017.109

https://www.diabetes.org/resources/statistics/statistics-about-diabetes#:~:text=Prevalence%3A%20In%202018%2C%2034.2%20million,of%20the%20population%2C%20had%20diabetes.&text=Undiagnosed%3A%20Of%20the%2034.2%20million,and%207.3%20million%20were%20undiagnos

https://www.kcl.ac.uk/news/spotlight/global-cost-of-diabetes-set-to-double-by-2030

https://www.kcl.ac.uk/news/spotlight/global-cost-of-diabetes-set-to-double-by-2030

https://www.worldobesity.org/news/world-obesity-day-all-countries-significantly-off-track-to-meet-2025-who-targets-on-obesity